What it covered
The study asked a straightforward question: was the pharmaceutical industry ready to adopt cloud computing, mobility, and strategic big data and analytics, and what would that mean for the operating model?
It combined academic review, a survey of industry practitioners, and lessons from a large transformation programme I was part of. The conclusions were often cautious: IT trends were seen as risk as much as opportunity, with security, privacy, and talent cited repeatedly as barriers.
Who it was written for
- CIOs, CTOs, and IT strategy leaders in pharma and biotech
- Transformation and operating-model leads in regulated life sciences
- Consultants and MBA students comparing adoption across industries
How to read it today
Treat it as a historical baseline. Many patterns hold; the technology names have changed. Pair it with current commentary on Insights, especially on AI, hybrid cloud, and data governance.
Key conclusions (2015)
Summarised from the executive summary. The full analysis is in the download.
No single playbook
Each organisation is distinctive. Adoption depends on multiple determinants, not one guaranteed framework.
Trends as risk and opportunity
Cloud, mobility, and BD&A brought agility, yet were often treated as threats until costs, security, and skills were addressed.
Combine for value
The greatest opportunity lay in combining trends to anticipate problems, not adopting each in isolation.
Recommendations that aged well
Revisit the operating model, invest in adoption, share information where appropriate, and act as a business partner, not only a technology supplier.
Get the free eBook
First name, last name, and LinkedIn profile URL are required to unlock the download.
Questions or speaking enquiries? Email